FDA bans unapproved gout treatments

FDA announced plans to ban unapproved gout treatments, favoring Mutual Pharmaceuticals' new version of the decades-old product, Colcrys. Hikma Pharma, which markets old-time colchicine, says its generics revenue growth will still come in at 20 percent. FDA release | Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.